AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 9,088,900 shares, an increase of 7.6% from the April 15th total of 8,450,700 shares. Currently, 27.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 758,900 shares, the days-to-cover ratio is currently 12.0 days.
In other AMAG Pharmaceuticals news, CEO William K. Heiden acquired 10,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The stock was bought at an average price of $10.70 per share, for a total transaction of $107,000.00. Following the purchase, the chief executive officer now owns 490,056 shares in the company, valued at approximately $5,243,599.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Elizabeth Scott Bolgiano acquired 5,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The stock was acquired at an average price of $10.93 per share, with a total value of $54,650.00. Following the purchase, the insider now owns 74,847 shares in the company, valued at approximately $818,077.71. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 328,016 shares of company stock valued at $2,904,577. Corporate insiders own 4.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. California Public Employees Retirement System boosted its stake in shares of AMAG Pharmaceuticals by 0.8% in the 4th quarter. California Public Employees Retirement System now owns 86,987 shares of the specialty pharmaceutical company’s stock valued at $1,321,000 after purchasing an additional 690 shares during the last quarter. Texas Permanent School Fund boosted its stake in shares of AMAG Pharmaceuticals by 4.2% in the 4th quarter. Texas Permanent School Fund now owns 22,600 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 909 shares during the last quarter. NumerixS Investment Technologies Inc boosted its stake in shares of AMAG Pharmaceuticals by 17.8% in the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,083 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of AMAG Pharmaceuticals by 1.1% in the 1st quarter. Rhumbline Advisers now owns 103,866 shares of the specialty pharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 1,125 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of AMAG Pharmaceuticals by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 285,332 shares of the specialty pharmaceutical company’s stock valued at $4,334,000 after purchasing an additional 1,613 shares during the last quarter.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.77). The business had revenue of $75.80 million during the quarter, compared to the consensus estimate of $90.13 million. AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same period last year, the business posted ($1.59) EPS. On average, equities research analysts predict that AMAG Pharmaceuticals will post -2.15 EPS for the current fiscal year.
A number of equities analysts have recently issued reports on AMAG shares. Cowen restated a “hold” rating and issued a $13.00 price objective on shares of AMAG Pharmaceuticals in a research note on Monday, June 24th. BidaskClub upgraded shares of Zai Lab from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 28th. Barclays restated a “hold” rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Zacks Investment Research raised shares of Hanmi Financial from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Finally, ValuEngine lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $16.92.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What is a portfolio manager?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.